Evidence map›Paper›PMID 41491997›Full record

ReviewCell death discovery2026

Sbno2-mediated tissue-resident alveolar macrophages: a novel therapeutic axis for sepsis-induced acute lung injury.

Jingyu Dai, Zhihai Wu, Jiayi Zhong, Xiaolong Wu, Yibin Liu, Qin Yang, Li Li, Shuyao Zhang, Junyong Zhong

Abstract readReview
In one paragraph

Review in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingyu Dai *Oncology Department, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, PR China.
Zhihai Wu *Oncology Department, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, PR China.
Jiayi Zhong *Shantou University Medical College, Shantou, Guangdong, PR China.
Xiaolong Wu *Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, PR China.
Yibin LiuOncology Department, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, PR China.
Qin YangOncology Department, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, PR China.
Li LiDepartment of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, PR China.
Shuyao ZhangDepartment of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, PR China. shuyao0754@ext.jnu.edu.cn.ORCID http://orcid.org/0000-0003-0292-4971
Junyong ZhongOncology Department, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, PR China. jayi321@163.com.ORCID http://orcid.org/0009-0008-5197-3394

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis-induced acute lung injury (ALI) is a critical clinical condition characterized by severe inflammation and alveolar epithelial barrier disruption, with limited effective treatments. Our study investigates the role of Sbno2-expressing tissue-resident alveolar macrophages (TR-AMs) in promoting alveolar epithelial cell (AEC) regeneration and barrier function in sepsis-induced ALI. Utilizing single-cell RNA sequencing (scRNA-seq), we identified significant upregulation of Sbno2 in TR-AMs, which correlated with enhanced AEC proliferation and reduced apoptosis. Functional assays demonstrated that Sbno2-expressing TR-AMs substantially supported alveolar structure regeneration in both in vitro and in vivo models. Knockout of Sbno2 in TR-AMs impaired AEC proliferation and compromised lung barrier integrity. Therapeutic administration of recombinant Sbno2 (rSbno2) in a sepsis-induced ALI mouse model alleviated lung injury, promoted AEC proliferation, and restored barrier function, highlighting Sbno2 as a potential therapeutic target for ALI. These findings provide novel insights into the molecular mechanisms of lung repair in sepsis-induced ALI and suggest that enhancing Sbno2 expression in TR-AMs could be a promising strategy for improving outcomes in patients with ALI.

Identifiers

PMID41491997
PMCPMC12876955

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.